lifestyle.goodsciencing.com

Author: Ensysce Biosciences

Ensysce Biosciences Expands Global Opioid Patent Portfolio

January 21, 2026
Ensysce Biosciences Receives EU Patent Expanding its First-in-Class ADHD Therapy with Built-In Abuse and Overdose Protection

January 8, 2026
Ensysce Biosciences Issues Annual Shareholder Letter

January 5, 2026
Ensysce Biosciences Achieves Major Milestone with Initiation of Enrollment in Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid

December 9, 2025